Reduction in Fibrotic Tissue Formation in Mice Genetically Deficient in Plasminogen Activator Inhibitor-1
- 31 August 2003
- journal article
- Published by Elsevier in The American Journal of Pathology
- Vol. 163 (2) , 445-452
- https://doi.org/10.1016/s0002-9440(10)63674-7
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (P50 HL56402, K08 HL04434)
This publication has 40 references indexed in Scilit:
- Plasminogen Activator Inhibitor-1 Deficiency Prevents Hypertension and Vascular Fibrosis in Response to Long-term Nitric Oxide Synthase InhibitionCirculation, 2001
- PAI-1 deficiency attenuates the fibrogenic response to ureteral obstructionKidney International, 2001
- Wound-healing defects in mice lacking fibrinogenBlood, 2001
- Liver Cirrhosis Is Reverted by Urokinase-Type Plasminogen Activator Gene TherapyMolecular Therapy, 2000
- Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.2000
- A Total Fibrinogen Deficiency Is Compatible with the Development of Pulmonary Fibrosis in MiceThe American Journal of Pathology, 2000
- Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.Journal of Clinical Investigation, 1997
- Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene.Journal of Clinical Investigation, 1996
- The urokinase receptor is required for human monocyte chemotaxis in vitro.Journal of Clinical Investigation, 1994
- The pathogenesis of bleomycin-induced pulmonary fibrosis in mice.1974